The SELECT trial, while a significant milestone, also underscores the importance of ensuring diverse trial populations for more accurate generalizability
In a recent update, the FDA said its Adverse Event Reporting Systems (FAERS) received reports of patients using these GLP-1 drugs suffering a form of hair loss known as alopecia, as well as suicidal ideation, and instances of aspiration in which food and liquids accidentally enter the lung
Because retatrutide is not a licensed medicine in the UK, the MHRA advises against its use outside of formal clinical trials or a named-patient pathway authorised by a responsible clinician
Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers
It has been found to cut A1C levels, which is a vital component in regulating blood sugar levels over an extended period
References Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetesstate-of-the-art